Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.

The Paragraph IV certification sought is with respect to applicable patents listed in the U.S. FDA’s Orange Book. Granules said it has also issued the requisite notice to the relevant parties in…
More news in Industry
IRDAI imposes ₹2 cr penalty on Star HealthJewellery demand remains resilient for Q3 despite gold price surge
U.S. FDA issues VAI classification to Natco Pharma’s FDF unit in Vizag